Episode 11 – Introducing biosimilar natalizumab
01 września 2025
In this episode of the Illuminoz podcast series, Bianca Stadler speaks with Professor Heinz Wiendl – neurologist and neuroimmunologist – about the first biosimilar approved for use in multiple sclerosis: biosimilar natalizumab (Tyruko®).
What was the development and regulatory pathway for this biosimilar? How does the approval process differ from that of originator biologics? And what clinical and pharmacokinetic data support its use?
This episode offers valuable insights for neurologists and healthcare teams considering biosimilars in their MS treatment strategies.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
